CA
CYCN icon

Cliff Asness’s Cyclerion Therapeutics CYCN Stock Holding History

Cliff Asness’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,113
Closed -$191K – 2204
2020
Q4 		$191K Buy
+3,113
New +$212K ﹤0.01% 2095
2020
Q3 		– Sell
-3,940
Closed -$466K – 2198
2020
Q2 		$466K Sell
3,940
-4,204
-52% -$352K ﹤0.01% 1768
2020
Q1 		$432K Buy
8,144
+776
+11% +$55.4K ﹤0.01% 1634
2019
Q4 		$401K Buy
+7,368
New +$688K ﹤0.01% 1823

Other funds holding CYCN

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Cliff Asness's CYCN Position: Q1 2021 in Review

Cliff Asness sold out of Cyclerion Therapeutics (CYCN) in Q1 2021, closing a stake of 3,113 shares — an estimated $191K sold.

Cliff Asness first reported a position in CYCN in Q4 2019 and held it in 4 quarters. The position peaked at $466K in Q2 2020. 70 funds tracked by Wall St. Rank hold CYCN as of Q1 2021.

  • Cliff Asness reported no remaining Cyclerion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Cliff Asness sold 3,113 Cyclerion Therapeutics shares in Q1 2021, an estimated $191K.
  • Cliff Asness first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 4 quarters.
  • Cliff Asness's Cyclerion Therapeutics position peaked at $466K in Q2 2020.
  • 70 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2021.

Based on AQR Capital Management's 13F filing for Q1 2021, filed 17 May 2021.